Dentsply Sirona (XRAY): Assessing Valuation Following Quarterly Miss, Impairment Charge, and Leadership Changes

Dentsply Sirona (XRAY) shares drew extra attention after the company’s third-quarter results missed expectations. Net sales fell, losses persisted, and a $263 million impairment charge highlighted ongoing challenges. Softer demand and tariffs also weighed on U.S. performance.

See our latest analysis for DENTSPLY SIRONA.

With sales declining, a significant impairment charge, and a change in the CFO seat all in the mix this quarter, Dentsply Sirona’s share price has lost momentum, posting a 1-month share price return of -15.9% and a steep year-to-date drop of -43.9%. In fact, the company’s 1-year total shareholder return sits at -40%, underscoring that both short- and long-term performance are under pressure amid shifting investor sentiment and heightened risk perception.

If the recent events at Dentsply Sirona have you reassessing your options, it could be the perfect time to broaden your search and discover fast growing stocks with high insider ownership.

After such a steep drop and ongoing challenges, is the recent pain already reflected in the stock price? Could this be a genuine buying opportunity if future growth surprises to the upside?

Most Popular Narrative: 34% Undervalued

With the current fair value estimate of $16.00 compared to a last close of $10.52, the dominant narrative suggests significant upside from present levels. The narrative’s estimate reflects carefully modeled assumptions about profits, future margins, and sector trends, positioning the stock as a value play among its peers.

Active cost reduction programs, operational streamlining, and supply chain optimization are in progress. Management indicates a stronger urgency to go "deeper and faster," potentially boosting EBITDA margin and cash flow generation through both lower SG&A and more efficient manufacturing.

Read the complete narrative.

Wondering what kind of turnaround could justify a much higher price? There is one core assumption in this narrative that could flip the script overnight. Find out which game-changing profitability target analysts are banking on to support their bullish outlook.

Result: Fair Value of $16.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent sales declines and rising tariff-related costs could quickly unravel the bullish case if operational improvements fail to materialize as expected.

Find out about the key risks to this DENTSPLY SIRONA narrative.

Build Your Own DENTSPLY SIRONA Narrative

If you see things differently or trust your own analysis more, you can quickly build your own view based on the data in just a few minutes. Do it your way.

A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Ready for More Smart Investment Ideas?

Stay one step ahead of the market. Put Simply Wall Street's powerful Screener to work for you and uncover opportunities that others are missing right now.

• Uncover companies with strong balance sheets and real earnings potential by checking out these 886 undervalued stocks based on cash flows that could be trading at bargain prices today.
• Snag great yields and pad your portfolio income, starting with these 16 dividend stocks with yields > 3% offering yields over 3% and solid fundamentals.
• Jump into the future of healthcare by searching these 32 healthcare AI stocks driving breakthroughs in medicine and technology.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com